Sunobinop, an investigational drug, is being evaluated as a potential treatment for interstitial cystitis/bladder pain syndrome (IC/BPS) and other conditions, including overactive bladder and alcohol 🍺 🍷 use disorder, by Imbrium Therapeutics.
- Sunobinop’s Potential for IC/BPS:
- Imbrium Therapeutics is evaluating 🤔 sunobinop as a potential treatment for IC/BPS.
- A phase 1b study in patients with overactive bladder (OAB) showed that sunobinop significantly reduced urinary urgency, frequency, and incontinence 🚽 episodes compared to placebo.
- The study also demonstrated greater efficacy in patients with more severe OAB, with no serious adverse events reported.
- Sunobinop is the first oral agent targeting sensory impulses triggering bladder symptoms, showing promise for OAB treatment 🥼.
Patients with interstitial cystitis experience very disruptive symptoms that can severely affect daily activities, work productivity, and overall quality of life. The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD, president and CEO of Purdue Pharma.
| Treatment | What it is / how it works | Current status / results | Potential pluses / concerns |
|---|---|---|---|
| Sunobinop | A novel oral compound that activates the nociceptin / orphanin-FQ peptide receptor (NOP), which is involved in bladder voiding and sensory pain. Imbrium Therapeutics+1 | Phase 1b signal-detection trial (2025). In that study, subjects on sunobinop had ~41% with moderate or marked improvement vs ~9% for placebo. Improvements included less urgency/frequency, less pain, larger void volumes. purduepharma.com | Promising as a systemic oral drug; if side effects are tolerable, could fill a gap. Needs larger trials to establish safety/long‐term efficacy. |
Sources 📑
TREATING INTERSTITIAL CYSTITIS 